To summarize the proposed mechanisms behind hypertension and QT interval prolongation associated with use of targeted systemic cancer therapies and provide recommendations for monitoring or managing these toxicities.
Summary
The cardiotoxic effects of targeted systemic cancer therapies represents a new paradigm of cancer treatment associated cardiovascular adverse events. National guidelines regarding optimal monitoring and management strategies for hypertension and QT interval prolongation associated with use of these therapies are lacking. While the pathophysiological drivers of hypertension due to targeted systemic cancer therapies differ by class of targeted therapy, general management strategies do not. Routine blood pressure monitoring throughout the duration of therapy is recommended for all agents. Patients who experience hypertension often can be treated with the addition or modification of antihypertensive therapies. Uncontrolled hypertension despite optimal medical management may require dose modifications or discontinuation of the targeted systemic cancer therapy. Electrocardiogram monitoring is recommended for patients who receive targeted therapies that may prolong the QT interval. Minimizing or managing drug interactions with other QT prolonging medications is recommended in addition to ensuring adequate electrolyte supplementation. Dose modifications or discontinuation of the targeted systemic therapy may be necessary for patients who experience QT interval prolongation.
Conclusions
Appropriate cardiovascular monitoring and timely management of treatment-emergent toxicities can optimize therapy for patients receiving targeted systemic cancer therapies associated with a risk of drug-induced hypertension or QT interval prolongation.
ManolisAAManolisTAMikhailidisDP, et al.
Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – part 1. Expert Opin Drug Saf2018;
17: 875–892.
2.
WickramasingheCDNguyenKLWatsonKE, et al.
Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Future Oncol2016;
12: 855–870.
3.
O'HareMMurphyKMookadamF, et al.
Cardio-oncology part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity. Expert Rev Cardiovasc Ther2015;
13: 519–527.
4.
ZamoranoJLLancellottiPRodriguez MunozD, et al.; ESC Scientific Document Group.
2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J2016;
37: 2768–2801.
5.
CuriglianoGCardinaleDSuterT, et al.; ESMO Guidelines Working Group.
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol2012;
23(Suppl 7): vii155–vii166.
ArmaniniDAndrisaniAAmbrosiniG, et al.
Role of adrenocorticotropic hormone in essential hypertension and primary aldosteronism. J Clin Hypertens (Greenwich)2017;
19: 287–289.
29.
FerrariR.RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract2013;
2013: 269–278.
30.
EltantawyAVallejosXSebeaE, et al.
Copanlisib: an intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma. Ann Pharmacother2019;
53: 954–958.
31.
MensahFABlaizeJPBryanLJ.Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Oncol Targets Ther2018;
11: 4817–4827.
32.
DoiTFuseNYoshinoT, et al.
A phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol2017;
79: 89–98.
33.
IsonGHowieLJAmiri-KordestaniL, et al.
FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res2018;
24: 4066–4071.
OkamotoLEShibaoCGamboaA, et al.
Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension2012;
59: 650–656.
36.
ZengCJosePA.Dopamine receptors: important antihypertensive counterbalance against hypertensive factors. Hypertension2011;
57: 11–17.
37.
CaldeiraDAlvesDCostaJ, et al.
Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One2019;
14: e0211228.
38.
ManoharSBansalAWanchooR, et al.
Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol2019;
94: E223–E225.
39.
DharmashankarKWidlanskyME.Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep2010;
12: 448–455.
40.
ManolisAAManolisTAMikhailidisDP, et al.
Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – part 2. Expert Opin Drug Saf2018;
17: 893–915.
41.
JamesPAOparilSCarterBL, et al.
2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA2014;
311: 507–520.
42.
WheltonPKCareyRMAronowWS, et al.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension2018;
71: e13–e115.
43.
MaitlandMLBakrisGLBlackHR, et al.; Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee.
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst2010;
102: 596–604.
44.
RiniBICohenDPLuDR, et al.
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst2011;
103: 763–773.
45.
SundarSDickinsonPD.Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Rep2012;
2012: 1–4.
46.
ChesonBDO'BrienSEwerMS, et al.
Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymphoma Myeloma Leuk2019;
19: 135–141.
47.
Cardizem(R) [package insert]. Bridgewater, NJ: Bausch Health US, LLC, 2020.
Coreg [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2017.
51.
AlexandreJMoslehiJJBersellKR, et al.
Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther2018;
189: 89–103.
52.
RabkinSWChengXB.Nomenclature, categorization and usage of formulae to adjust QT interval for heart rate. World J Cardiol2015;
7: 315–325.
53.
MulunehBRichardsonDRHicksC, et al.
Trials and tribulations of corrected QT interval monitoring in oncology: rationale for a practice-changing standardized approach. JCO2019;
37: 2719–2721.
54.
Food and Drug Administration: clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs – questions and Answers (R3). Guidance for Industry (2017, accessed 26 January 2020).
55.
Food and Drug Administration: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005, accessed 26 January 2020).
56.
Porta‐SánchezAGilbertCSpearsD, et al.
Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc2017;
6: e007724.
57.
Zykadia(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.
58.
Xalkori(R) [package insert]. New York, NY: Pfizer Laboratories Div Pfizer Inc., 2019.
Tykerb(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.
65.
Tasigna(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.
66.
Tagrisso(R) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2019.
67.
Kisqali(R) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2019.
68.
Zelboraf(R) [package insert]. South San Francisco, CA: Genentech, Inc., 2018.
69.
UmarRM.Drug-drug interactions between antiemetics used in cancer patients. J Oncological Sci2018;
4: 142–146.
70.
BryggerLHerrstedtJ; Academy of Geriatric Cancer Research (AgeCare).
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf2014;
13: 1407–1422.
71.
FDA Drug Safety Communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) (accessed 15 April 2020).
72.
EttingerDSBergerMJBarvourS, et al. Antiemesis (2020, accessed 15 April 2020).
73.
DoggrellSAHancoxJC.Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf2013;
12: 421–431.
74.
FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) (accessed 15 April 2020).
75.
Sancuso (R) [package insert]. Bedminster, NJ: Kyowa Kirin, Inc., 2017.
76.
Aloxi(R) [packge insert]. Woodcliff Lake, NJ: Eisai Inc., 2015.
77.
GrandeEKreisslMCFilettiS, et al.
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther2013;
30: 945–966.
78.
BadenLRSwaminathanS. Prevention and treatment of cancer-related infections. In: NCCN clinical practice guidelines in oncology. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2017, p. INF-1 through p. MS-113.
79.
Cresemba [package insert]. Northbrook, IL: Astellas Pharma US Inc., 2019.
